These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 25772548)

  • 1. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
    Araki E; Tanizawa Y; Tanaka Y; Taniguchi A; Koiwai K; Kim G; Salsali A; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2015 Jul; 17(7):665-74. PubMed ID: 25772548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
    Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
    Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
    DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Ridderstråle M; Rosenstock J; Andersen KR; Woerle HJ; Salsali A;
    Diabetes Obes Metab; 2018 Dec; 20(12):2768-2777. PubMed ID: 29961998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    Ridderstråle M; Andersen KR; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):691-700. PubMed ID: 24948511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
    Inagaki N; Watada H; Murai M; Kagimura T; Gong Y; Patel S; Woerle HJ
    Diabetes Obes Metab; 2013 Sep; 15(9):833-43. PubMed ID: 23565760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
    Ferrannini E; Seman L; Seewaldt-Becker E; Hantel S; Pinnetti S; Woerle HJ
    Diabetes Obes Metab; 2013 Aug; 15(8):721-8. PubMed ID: 23398530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
    Matthaei S; Bowering K; Rohwedder K; Sugg J; Parikh S; Johnsson E;
    Diabetes Obes Metab; 2015 Nov; 17(11):1075-84. PubMed ID: 26212528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes.
    Lewin A; DeFronzo RA; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Mar; 38(3):394-402. PubMed ID: 25633662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
    Ferrannini E; Berk A; Hantel S; Pinnetti S; Hach T; Woerle HJ; Broedl UC
    Diabetes Care; 2013 Dec; 36(12):4015-21. PubMed ID: 24186878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.
    Kadowaki T; Haneda M; Inagaki N; Terauchi Y; Taniguchi A; Koiwai K; Rattunde H; Woerle HJ; Broedl UC
    Adv Ther; 2014 Jun; 31(6):621-38. PubMed ID: 24958326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
    Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
    Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
    Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ;
    Diabetes Obes Metab; 2015 Oct; 17(10):936-48. PubMed ID: 26040302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
    Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
    Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
    Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
    Matthaei S; Aggarwal N; Garcia-Hernandez P; Iqbal N; Chen H; Johnsson E; Chin A; Hansen L
    Diabetes Obes Metab; 2016 Nov; 18(11):1128-1133. PubMed ID: 27403645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
    Vilsbøll T; Ekholm E; Johnsson E; Dronamraju N; Jabbour S; Lind M
    Diabetes Care; 2019 Aug; 42(8):1464-1472. PubMed ID: 31167892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.